New clinical study on patented olive leaf extract Bonolive® shows joint health benefits

Maastricht, Netherlands, February 8th, 2022

Press release
Therapeutic Advances in Musculoskeletal Disease has recently published a new clinical study with Bonolive®, a patented bone and joint health ingredient based on olive polyphenol. The new publication suggests that Bonolive® may improve joint functional capacity and reduce knee pain.

Press release new publication on Bonolive BioActor

New randomized clinical trial published with Bonolive®

Bonolive® is a natural polyphenol extract from olive leaves, developed by BioActor. Bonolive® was already studied for bone protecting effects in post-menopausal women and is covered by a patent on the bone health application of the extract.

A recent randomized, double-blind, placebo-controlled trial including 124 subjects demonstrated a large and significant treatment effect of Bonolive® in improving joint discomfort and reducing pain in subjects with knee pain.

Participants in the study received either a placebo or supplementation with a 125mg capsule containing Bonolive® (40% oleuropein), twice a day for 6 months.

The conclusion indicates that Bonolive® was able to improve the KOOS score (Knee Injury and Osteoarthritis Outcome) and to reduce walking pain in subjects with knee pain.

The researchers from the Liege University Hospital suggested that oleuropein may relieve nociceptive pain triggered by the mechanical strain because of its calcium channel blocker property.

N-type calcium channels are indeed important for neuronal excitability and play a role in pain genesis. As a blocker of these channels, Bonolive® seems to produce an antinociceptive effect, thus reducing pain.

These benefits were not associated with any adverse effect after 6 months of treatment, showing excellent tolerability of the extract. Moreover, the study confirmed yet again the great bioavailability of Bonolive®. The main metabolites of the extract, oleuropein aglycone, hydroxytyrosol and homovanillyl alcool were measured and showed a rapid rise in the urine of all treated subjects.

This study was conducted in the context of a collaboration with Nestlé Health Science, aiming to strengthen the scientific evidence for the benefits of Bonolive®.

“We are proud of the results achieved thanks to this collaboration”, says Hans van der Saag, CEO and founder of BioActor. “Mobility is extremely important for the quality of life and a core indicator of healthy ageing. These new scientific insights on Bonolive® will allow us to expand its applications to mobility targeting products”.

About BioActor

BioActor, based at the Maastricht Health Campus, Netherlands, is a life science company that has developed a range of proprietary bioactive ingredients for the nutrition & consumer health industries. The company focuses on the development of plant-based health ingredients for active living and healthy ageing. The goal is to provide the nutrition & consumer health industries with clinically tested innovations that confer a real health benefit to the consumer.

Feel free to contact BioActor via for more information on the possibilities Bonolive® has to offer.

Further information can be found on: and